Flibanserin for hypoactive sexual desire disorder: place in therapy

Faina Gelman, Jessica Atrio

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.

Original languageEnglish (US)
Pages (from-to)16-25
Number of pages10
JournalTherapeutic Advances in Chronic Disease
Issue number1
StatePublished - Jan 2017


  • female sexual interest and arousal disorders
  • flibanserin
  • hypoactive sexual desire disorder
  • libido
  • little pink pill
  • sexual dysfunction

ASJC Scopus subject areas

  • Medicine (miscellaneous)


Dive into the research topics of 'Flibanserin for hypoactive sexual desire disorder: place in therapy'. Together they form a unique fingerprint.

Cite this